Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Turk Ilac Ve Serum Sanayi Anonim Sirketi TRY 1.98, price TRY 0.90, upside +120.1%, quality 21 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Turk Ilac Ve Serum Sanayi Anonim Sirketi for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range 0.9000 TRY – 5.90 TRY · fair‑value band 1.39 TRY – 2.58 TRY · the 0.9000 TRY price screens below the 1.98 TRY fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Turk Ilac Ve Serum Sanayi Anonim Sirketi in your weekly email
Every Wednesday you see whether Turk Ilac Ve Serum Sanayi Anonim Sirketi is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices.
Show more
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. Turk Ilac Ve Serum Sanayi Anonim Sirketi was founded in 2010 and is headquartered in Ankara, Turkey.
Stock analysis
Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC) currently trades at 0.9000 TRY, while our model-based Fair Value estimate is 1.98 TRY, implying the stock looks roughly 54.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 3.24 TRY per share, and 14 of the 14 models we run sit above the 0.9000 TRY price.
Bear case: the Asset-Based group reads lowest at 1.24 TRY, and 0 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 1.39 TRY (bear) to 2.58 TRY (bull), the price of 0.9000 TRY sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Turk Ilac Ve Serum Sanayi Anonim Sirketi reported revenue of 2.6B TRY in FY2024 versus 200M TRY in FY2020, a compound +89.4%/yr. Reported net income was 72.4M TRY in FY2024, compounding +21.4%/yr from FY2020.
Key figures
Market cap 933M TRY (≈ $19.1M) · P/S ratio 0.18 · EPS (TTM) −0.5000 TRY · Net margin 2.8% · Return on equity −1.1% · Return on assets (EBIT) 13.0% · Operating margin 20.4% · Revenue (TTM) 5.1B TRY.
What moves the price
The share trades about 78% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 120%, TRILC screens cheaper than that median.
Fair Value models
Bear 1.39 TRYFair Value 1.98 TRYBull 2.58 TRY
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−7.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.0%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.5%
’18
’19
’20
’21
’22
’23
’24
What shareholders gained per year (last 5 years), in TRY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TRY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+13.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.6%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 21%
Compare Turk Ilac Ve Serum Sanayi Anonim Sirketi with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 621 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score21 · Bottom 25%
Fair Value upside+120.1% · Top 25%
Profitability
Return on assets12.3% · Top 25%
Net margin (TTM)−0.4% · Below median
Operating margin (TTM)20.4% · Top 25%
Growth and dividend
Revenue growth65.1% · Top 25%
Balance sheet
Debt / equity0.48× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Turk Ilac Ve Serum Sanayi Anonim Sirketi Fair Value". https://www.fairvalue-calculator.com/stock/TRILC
Frequently asked questions
Is Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 1.98 TRY versus a price of 0.9000 TRY, about +120% upside (undervalued).
What is the fair value of TRILC?
Our model-based fair value for Turk Ilac Ve Serum Sanayi Anonim Sirketi is 1.98 TRY (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.9000 TRY.
What is the quality score of TRILC?
Turk Ilac Ve Serum Sanayi Anonim Sirketi has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
Our model-based price target is the fair value of 1.98 TRY (as of Sep 27, 2026) from 14 valuation models. Cautious scenario 1.39 TRY, optimistic scenario 2.58 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Turk Ilac Ve Serum Sanayi Anonim Sirketi stock forecast for 2026?
Our models put fair value at 1.98 TRY, about +120% upside versus a price of 0.9000 TRY (undervalued). Cautious scenario 1.39 TRY, optimistic scenario 2.58 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
Turk Ilac Ve Serum Sanayi Anonim Sirketi reported trailing-twelve-month revenue of about 5.1B TRY (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Turk Ilac Ve Serum Sanayi Anonim Sirketi it is 1.98 TRY per share (as of Sep 27, 2026), against a price of 0.9000 TRY. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Turk Ilac Ve Serum Sanayi Anonim Sirketi stock overvalued or undervalued in 2026?
As of Sep 27, 2026, TRILC trades below its calculated fair value: price 0.9000 TRY, fair value 1.98 TRY, a gap of about +120% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TRILC?
No. The price is what the market pays today (0.9000 TRY); the fair value is what the company's own numbers justify (1.98 TRY). For Turk Ilac Ve Serum Sanayi Anonim Sirketi the two are 1.08 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Turk Ilac Ve Serum Sanayi Anonim Sirketi worth?
The market values Turk Ilac Ve Serum Sanayi Anonim Sirketi at about 933M TRY (market capitalisation, as of Sep 27, 2026). Per share that is 0.9000 TRY; our models calculate a fair value of 1.98 TRY per share.
What do the bullish and bearish scenarios say about TRILC?
Our models span a range for Turk Ilac Ve Serum Sanayi Anonim Sirketi: cautious scenario 1.39 TRY, base 1.98 TRY, optimistic 2.58 TRY per share (as of Sep 27, 2026, price 0.9000 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
Balance-sheet figures for Turk Ilac Ve Serum Sanayi Anonim Sirketi (as of Sep 27, 2026): return on equity −1.1%, debt of 0.48 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is TRILC from its 52-week high?
Turk Ilac Ve Serum Sanayi Anonim Sirketi trades at 0.9000 TRY, about 78% below its 52-week high of 4.05 TRY and at the low of 0.9000 TRY (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of 1.98 TRY is for.
Which stocks are comparable to Turk Ilac Ve Serum Sanayi Anonim Sirketi?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Turk Ilac Ve Serum Sanayi Anonim Sirketi stock attractive at the current price?
The data as of Sep 27, 2026: price 0.9000 TRY, calculated fair value 1.98 TRY (+120%), Quality Score 21/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TRILC calculated?
We run Turk Ilac Ve Serum Sanayi Anonim Sirketi through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.98 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Turk Ilac Ve Serum Sanayi Anonim Sirketi currently trades 120 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
The closing price on Sep 25, 2026 was 0.9000 TRY. Our model-based fair value is 1.98 TRY, about +120% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Turk Ilac Ve Serum Sanayi Anonim Sirketi right now?
The large discount to fair value meets weak quality (21/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (1.39 TRY). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.39 TRY to 2.58 TRY) leaves room in how you read the outcome.
Key figures of Turk Ilac Ve Serum Sanayi Anonim Sirketi
How large is the market capitalisation of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
The market capitalisation of Turk Ilac Ve Serum Sanayi Anonim Sirketi is 933M TRY (≈ $19.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
The price-to-sales ratio of Turk Ilac Ve Serum Sanayi Anonim Sirketi is 0.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
Earnings per share at Turk Ilac Ve Serum Sanayi Anonim Sirketi are −0.5000 TRY. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
The net margin of Turk Ilac Ve Serum Sanayi Anonim Sirketi is 2.8% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
The return on equity (ROE) of Turk Ilac Ve Serum Sanayi Anonim Sirketi is −1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
On an EBIT basis the return on assets of Turk Ilac Ve Serum Sanayi Anonim Sirketi is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
The operating margin of Turk Ilac Ve Serum Sanayi Anonim Sirketi is 20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
Revenue at Turk Ilac Ve Serum Sanayi Anonim Sirketi is growing +65.1% versus a year earlier (3y avg +56.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC)?
Earnings per share at Turk Ilac Ve Serum Sanayi Anonim Sirketi are growing +68.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC) generate?
The free cash flow of Turk Ilac Ve Serum Sanayi Anonim Sirketi is −530M TRY (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Turk Ilac Ve Serum Sanayi Anonim Sirketi (TRILC) carry?
The net debt of Turk Ilac Ve Serum Sanayi Anonim Sirketi is 1.6B TRY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Turk Ilac Ve Serum Sanayi Anonim Sirketi in the live analysis
One click puts Turk Ilac Ve Serum Sanayi Anonim Sirketi on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
